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ABSTRACT
Dexamethasone, a powerful corticosteroid, is a frequently used drug in the realm of veterinary
medicine. However, many times it is used without prior knowledge as to why or how it may produce
the desired effect, or without consideration as to the best method of administration.
The purpose of this project is two-fold. First, it will consist of some basic research in order to
clarify the mode of action of dexamethasone. In brief, corticosteroids are hormones produced by the
adrenal gland, which is located adjacent to the kidney. The production of corticosteroids is subject
to feedback regulation, where a build-up of corticosteroid will shut down the production of any
further hormone.
The second phase of this project consists of a field study using six equines. Dexamethasone, a
synthetic corticosteroid, was administered both IV (intravenously) and IM (intramuscularly) to
determine the effects on regulation of the production of corticosteroids. The initial hypothesis was
that blood cortisol levels would be equally suppressed in horses given dexamethasone IV as in those
given dexamethasone IM. The final results of the study served to support this hypothesis.
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CORTICOSTEROIDS: A LOOK AT BASIC STRUCTURE AND
FUNCTION
INTRODUCTION
The human body is undeniably complicated. Yet in its complexity, it is incredibly
efficient and accurate in its functional abilities. One example of this is its ability to
synthesize and respond to a group of hormones known as glucocorticoids (or
glucocorticosteroids), produced by the adrenal cortex. In this paper, the glucocorticoids will
be introduced, covering areas of basic structure, pathway of synthesis, secretion and binding
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All of the steroid honnones (including glucocorticoids) have the some basic core structure,
consisting of three six-carbon rings and one five-carbon ring. In order for them to have their
anti-inflammatory and glucogenic ability, they must have a functional hydroxyl group (-OH)
at carbon 11. Additionally, they nlust have a functional-OH group at carbons 21 and 17 in
order to be maximally active. In this form, with an -OH at carbons 21 and 17, the steroid is
"said to be in its alcohol fonn. As such, it is classified as a lipid with the characteristic result
that it is insoluble in water.
Because of its insolubility, a steroid will require a protein carrier in order to travel in an
aqueous media (i.e. the plasma). The steroid will then be released into its target cells from
the protein-honnone complex fairly slowly, in contrast to some synthetic steroids which are
-1-

water soluble, do not require a carrier, and are released quickly to their targets.
Additionally, there are different ways in which steroids can be chemically modified. Using
hydrocortisone as an example, there is esterification at carbon 21. The addition of succinate
or phosphate at this location will result in a compound that is truly water soluble. However,
esterification at carbon 21 with butylacetate, acetate, acetonide, methyl acetate, dipropionate,
or pivalate causes the formation of a water insoluble ester form of the lipid that traverses
membranes much more slowly than the succinate and phosphate forms. However, since this
causes the hydrocortisone to be absorbed more slowly, it also tends to increase the duration
of its action.
However, in order to be active, these esters must be hydrolyzed after crossing the
membrane in order to convert the carbon at position 21 back to its active -OH form. This
conversion, which takes place intracellularly, occurs most rapidly for phosphate and
succinate esters, while other forms take longer.
There are also several alterations which can be made to the basic structure of
hydrocortisone that produce changes in its activity. Fonning a double bond between carbons

1 and 2, adding fluorine, adding a methyl group, and adding an -OR group all can lead to
increased anti-inflammatory potency and increased gluconeogenic potency_

BIOSYNTHESIS
The biosynthesis of glucocorticoids begins with the breakdown of cholesterol. The
pathway for the formation of cortisol, the most common glucocorticoid in humans, is known
-2-

to be cholesterol ---> pregnenolone ---> progesterone ---> 17-hydroxyprogesterone --->
cortisol. The convertion of cholesterol to 5-pregnenolone is carried out by a series of
enzymes found in the mitochondria of the adrenal cortex. The fITst reaction results in the
formation of a 2Oct..-hydroxyl in the side chain of the cholesterol molecule by a 2(){hydroxylase enzyme, followed by hydroxylation at the 22 position by 22-hydroxylase
enzyme, yielding 20x -22)-dihydroxycholesterol. Both of the hydrolase enzymes require
NADPH for the introduction of molecular oxygen to form the hydroxyl group. Then, a
cleavage occurs between the hydroxyl groups at the 20 and 22 positions by a desmolase
enzyme. This yields two products, 5-pregnenolone and isocaproid aldehyde. An interesting
fact which will bear more importance later on in this paper is that the reaction sequence of
cholesterol ---> 5-pregnenolone in the mitochondria has been considered to be one of the
principal sites at which ACTH is able to regulate steroidogenesis.
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The enzymes mvolveoln th~ patlfway of cholesterol ---> 5-pregnenolone can be stimulated

by the metabolism of citric acid cycle substrates such as isocitrate, malate, and succinate,
which generate reducing equivalents for the respiratory chain leading to steroid
hydroxylation. They can also be stimulated by an increased rate of reduction ofNADP+
generated from the glucose-6-phosphate dehydrogenase reaction found in the pentose
phosphate pathway. Additionally, high levels of ACTH in the blood can also stimulate the
-3-

conversion of cholesterol to pregnenolone.
The next step in the sequence of steroidogenesis sees the chemical conversion of
pregnenolone into progesterone, a series of reactions which also occur in the mitochondria
of the adrenal cortex. The fITst reaction is the removal of two hydrogens from the -CHOH
group at position 3 by a 3-hydroxysteroid dehydrogenase specific for pregnenolone, which
uses NAD+ as an electron acceptor. Thus, the enzyme converts the 3-hydroxyl group to a
3-ketone. The NADH formed may be reoxidized in the mitochondrial electron-transport
sequence. The second enzyme in this sequence is called 45 -3-ketosteroid isomerase and
results in the shift of the double bond from the 5 to the 4 position, yielding the product
progesterone.
The final two steps in the formation of cortisol are less complex. Progesterone is
converted to 1']PC - Hydroxyprogesterone by the enzyme 170( -Hydroxylase, which utilizes
NADPH as an electron donor. The enzymes 21 and 11 hydroxylases then convert 170< hydroxyprogesterone into 171{ - hydroxycorticosterone (hydrocortisone). This completes the
pathway of the convertion from cholesterol ---> hydrocortisone.

-4-

As the synthesis of hydrocortisone occurs in the mitochondria of the adrenal cortex, it is
useful to examine the system by which this synthesis is controlled. The hypothalamus, the
anterior portion of the pituitary gland, and higher centers in the brain all work together to
regulate the activity of the adrenal cortex and thus the levels of glucocorticosteroids in the
blood. In this physiological pathway, the higher centers of the brain may send nervous
signals to the hypothalamus.

The hypothalamus responds by releasing Corticotropin

Releasing Factor (CRF) into the blood supply, allowing it to be carried to the anterior
pituitary. The CRF then stimulates the anterior pituitary to release Adrenocorticotropic
Honnone (ACTH). ACTH travels in the blood stream to the adrenal cortex where it causes
the release of hydrocortisone into the animals blood stream, thus being distributed to all
tissues of the body.

eyc:lt>,',,:
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The fITst one
involves steroid feedback, where the level of hydrocortisone in the plasma regulates further
hydrocortisone release from the adrenal cortex by a feedback mechanism. This feedback
mechanism occurs at the level of the hypothalamus. Additionally, it is interesting to note
that the hypothalamus cannot tell the difference between hydrocortisone and some of the
-5-

chemically synthesized analogues such as Prednisolone, Dexamethasone, or Flumethasone.
Thus, injection with any of these drugs will lead the hypothalamus to conclude that levels
of hydrocortisone are high, thus decreasing production of CRF. An interesting study
published by Altemus et al. in 1997 examined the reduced sensitivity to glucocorticoid
feedback and reduced glucocorticoid receptor mRNA expression in the luteal phase of the
menstrual cycle. The results indicated that reduced glucocorticoid feedback regulation of
the hypothalamus-pituitary-adrenal axis may playa role in the generation of the common
premenstrual symptoms of irritability and dysphoria.
The second control mechanism used involves the nervous system. As the nervous system
is sensitive to changes in environment, it may respond by sending stimuli to the higher
centers of the brain, beginning the pathway that leads to the production of hydrocortisone.
By this means, animals are able to adapt to stress. Hannful stress stimuli such as fear, noise,
allergic reactions, and trauma tum this system on and increase the release of hydrocortisone.

GL YCOL YSIS AND GLUCONEOGENESIS
One of the important functions of glucocorticosteroids in the body is their role in the
production of glucose from short-chain precursors by gluconeogenesis. In this process,
glucocorticosteroids act to inhibit protein synthesis in peripheral tissues, thus releasing free
amino acids from muscle and other tissues to the liver. Once in the liver, these amino acids
then undergo transamination and other reactions to fonn pyruvate or oxalacetate, and then
eventually are converted into glucose by the gluconeogenic pathway. The nitrogen from the
-6-

amino acids is converted to urea by the liver. Furthennore, glucocorticosteroids also
increase the breakdown of lipids in adipose tissues, thus releasing free fatty acids and
glycerol. Glycerol is a precursor of glucose in the liver, whereas free fatty acids inhibit the
utilization of glucose by the liver. Thus, the initial effects of glucocorticosteroids is to
increase amino acid precursors for synthesis of glucose and, due to an increase in free fatty
acid from adipose tissue, to decrease the activity of enzymes involved in the breakdown of
glucose.
There are some additional early effects of glucocorticosteroids, although these seem to be
secondary. Firstly, they induce the synthesis of transaminases which are involved in the
fonnation of keto acid precursors from amino acids. Additionally, they seem to stimulate
the synthesis of gluconeogenic enzymes concerned in the synthesis of glucose from the keto
acids.
However, it should be noted that the action of the glucocorticosteroids can also have some
disastrous effects if used in excess.

A study perfonned in 1997 by McKay et al.

demonstrated that some common side effects of corticosteroid therapy include muscle
weakness and atrophy, which in part are mediated by the induction of glutamine synthetase.

Additionally, reabsorption of bone matrix along with calcium, possible increased blood
sugar, and increased glycogen deposition in the liver are also seen to occur. Furthennore,
some of the glucose which is produced in excess of the body's needs may be converted into
fat.
When the levels of sugar in the blood become low, two honnones are released. Glucagon,
-7-

the first honnone indirectly activates the enzyme phosphorylase a in the liver, leading to the
breakdown of glycogen to fonn glucose. It also activates liver lipases for an increased
breakdown of liver lipid with a release of free fatty acids and glycerol, the effects of which
have already been examined. Epinephrine, the other honnone released in response to low
blood sugar, leads to an increase in phosphorylase a. Like glucagon, it also stimulates lipase
in the adipose tissues, thereby releasing free fatty acid and glycerol. But is also has an effect
in stimulating the release of lactate from muscle, thus providing some precursors for
gluconeogenesis. In addition, the most pertinent point is that epinephrine also is apparently
a mediator in stimulating the release of ACTH from the anterior pituitary in response to a
decrease in blood glucose. This increase in ACTH stimulates the adrenal cortex for an
increased production of corticosteroids.

GLUCOCORTICOSTEROIDS AND THE IMMUNE RESPONSE

In addition to the effects of the steroid honnones on gluconeogenesis and glycolysis, the
glucocorticosteroids are also important in tlleir antiallergic and antiinflammatory actions.
They are able to cause an initial lysis of the lymph nodes with increased release of
antibodies. However, there is ultimately a decreased production of antibodies. The overall
effect is the suppression of the function of the lymphoid tissues, the tissues responsible for
the production of antibodies. Additionally, the glucocorticosteroids decrease the cellular
response to infection by decreasing the phagocytic ability of neutrophils and lymphocytes,
thereby reducing the inflammation without clearing up the infection. However, the actual
-8-

neutrophil count usually increases, although their activity is decreased.

Additionally,

glucocorticosteroids are able to decrease the formation of histamine and histamine-like
substances in cells, thereby reducing the allergic response. Since they also cause a decrease
in the eosinophil count, they can lead to a decrease in inflammation. Eosinophils are
abundant at sites of immediate hypersensitivity reactions, and in this setting they contribute
to tissue injury and inflammation. By lowering their count, glucocorticosteroids held
decrease visible inflammation.
Furthermore, glucocorticosteroids have been shown to increase the stability of cell
membranes and lysosomal membranes, thus decreasing the release of inflammation
enhancing toxic products from injured cells and from lysosomes, as well as decreasing the
cellular insult of toxins. By stabilizing these membranes, the activation of lipases and
phospholipases is prevented, thus preventing the supply of free arachidonic acid that triggers
the formation of eicosanoids. Finally, glucocorticosteroids inhibit prostaglandin production
by macrophages. Prostaglandins, which are part of the 20 carbon containing atoms known
as "eicosanoids", are known to stimulate inflammation, and thus their inhibition would
partially account for the decrease in inflammation observed upon injection of an individual
with glucocorticosteroids.
Finally, it is also known that glucocorticoid hormones are able to inhibit T-cell growth and
activation. A recent study performed by Migliorati et al. has suggested that the downmodulation of the T -cell receptor expression is due to the diminution of T -cell receptor gene
products in cells treated with exogenous glucocorticoids.
-9-

GLUCOCORTICOID RECEPTORS
At the cellular level, the many effects of glucocorticosteroids are medicated by the glucocorticoid
receptor. These receptors appear to be located in the cytoplasmic compartment of the cell, and thus
the first step in glucocorticoid action is for the hormone to gain entry into the cell. Generally, steroid
hormone uptake is generally considered to occur by simple diffusion, but it is possibly that specific
carriers are involved in steroid hormone uptake. Following this entry into the cytoplasm, the
hormone must bind to its appropriate receptor.

The glucocorticoid receptor is a relatively

nonabundant protein in cells, and is distinguishable by two basic characteristics. Firstly, it binds
hormones with high affinity. This high affinity is necessary because of the low concentrations at
which glucocorticoid hormones are generally present within the cell. Secondly, the glucocorticoid
receptor binds hormones with a high degree of specificity, and thus has very low affinity for other
classes of steroid hormones (i.e. androgens, estrogens). Additionally, the association between the
glucocorticoid receptor and its ligand is noncovalent. An interesting fact is that several transition
metals and their anions, including cadmium, arsenite, and selenite can inhibit glucocorticoid binding
to receptors. A study published by Telford and Fraker in 1997 shoed that zinc has an inhibitory effect
as well. After this receptor/ligand binding takes place, the receptor undergoes activation to a DNAbinding form. In the absence of hormone, the receptor is unable to bind DNA, but the binding of the
hormone converts it into its active form. Subsequently, the glucocorticoid receptor translocates into
the nucleus of the cell. Because of its rather large size (approximately 97 kd), it is most likely that
the receptor/ligand complex enters the nucleus via a facilitated transport mechanism rather than by
simple diffusion.

Finally, the glucocorticoid receptor will associate with specific sequences in the

genome which are known as glucocorticoid response elements. These response elements regulate
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the rate of transcription initiation from nearby promoters, causing an increase in the transcription of
specific genes.

For example, a study performed by Nuglozeh et al. In 1997 showed that

glucocorticoids have transcriptional and posttranscriptional effects on rat mesenteric artery cells
through glucocorticoid receptors. The glucocorticoid response element has a consensus sequence
ofTGTTCT, and has been detected as close as 39 base pair and as far as 2.6 kilobase pair upstream
of the transcription start site, and between 100 base pair and 8 kilobase pair downstream from the
initiation site. Additionally, there is also evidence that the glucocorticoid receptor is also able to act
posttranscriptionally to influence the levels of rrtRNA present, either by altering RNA stability or by
stimulating the transport of specific RNA species from the nucleus to the cytoplasm.

It is now known that the different regions of the glucocorticoid receptor have different functions,
and thus are considered separate domains. These discoveries were made when the receptor was
incubated with trypsin, resulting in three receptor fragments. The first two fragments arise from the
carboxy terminal half of the receptor, where they bind DNA and hormone, respectively. The third
fragment stems from the amino terminal of the receptor, and it reacts with most anti-receptor
antibodies, which are often used in the purification of the protein. Because this third domain is able
to bind to antibodies, it is thought that it constitutes the exposed surface when the receptor is in its
native conformation.
As was already mentioned, it appears that the receptor is inactive and unable to bind DNA when

in its unbound state. The process whereby hormone binds to its receptor and mediates a change to
the DNA-binding state is known as "receptor activation". Basically, there are two generally models
of receptor activation. In the first, known as the oligomer dissociation model, the oligomeric
structure renders the DNA-binding site inaccessible for interaction with DNA. On binding hormone,
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the oligomer dissociates, and thus exposes the DNA-binding site on the receptor. The second model
of activation is referred to as the conformational model. In this model, the function of the DNA
binding region is repressed by the steroid-binding domain.

When the hormone binds, the

conformation of the receptor changes, rendering the DNA-binding site accessible to DNA. Generally
speaking, these two models are extremely simplified, because there are additional factors involved
in activation. One example has been termed "modulator". Modulator is a phosphoglyceride that
functions as an endogenous inhibitor of glucocorticoid receptor activation.
The intracellular concentration of glucocorticoid receptors is largely responsible for the magnitude
of the cellular response to glucocorticoids.

Studies have indicated that the intracellular

concentration of glucocorticoid receptors is under autoregulatory control.

Thus,

many

glucocorticoids are able to downregulate the level of their own receptor. This downregulation is
relatively slow, taking at least 24 hours of steroid exposure to cause a notable decrease in receptor
content. Furthermore, on removal of the agonist, the glucocorticoid receptor downregulation is
reversed. During the period of receptor repletion, no altered forms of the glucocorticoid receptor
have been identified. There are several possible mechanisms responsible for the autoregulation. In
the first, the intracellular concentration of receptors may be determined by modulation of receptor
half-life. Some studies have shown that the half-life of the glucocorticoid receptor appears to be
shorter in the presence of hormone than in the absence of hormone. Secondly, the intracellular
receptor concentration can be regulated at the transcriptional level. Thus, the level of receptor
mRNA is decreased in response to glucocorticoids. It appears that the glucocorticoid receptor
downregulation may be caused by an interaction of the receptor protein with its own gene. Thirdly,
the receptor may be degraded by proteolysis, as there several calcium dependent enzymes that can
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degrade receptors are known to exist at specific loci. Finally, it is possible that the receptor my exist
in two forms, on an active hormone-binding state and one an inactive nonhormone-binding state. It
is possible that the conversion to the steroid-binding form requires the hydrolysis of ATP. This was
confirmed in an experiment which showed that the receptor binding capacity of the IM-9 line of
human lymphyoblasts was directly related to the ATP levels when cells were incubated under energy
limiting conditions. This conversion from the nonhormone binding to the hormone binding form was
both reversible and rapid. The exact function of the ATP is unknown. It is possible that the receptor
maybe phosphoylated by ATP in an enzyme dependent reaction. Recently, Miller et al. presented
the hypothesis that the receptor is itself a kinase, and is capable of autophosphorylation in the
presence of ATP. However, it remains uncertain whether phosphorylation actually controls binding
capacity or whether the ability to bind steroids may depend more on the receptors ability to form a
complex with ATP.
Additionally, a recent study published by Numi et al. examined the participation of tyrosine kinase
in the regulation of the glucocorticoid receptor by using the tyrosine kinase inhibitor herbmycin A.
Their findings showed that tyrosine kinase is necessary for maintaining the level of glucocorticoid
receptor protein and its affinity of binding sites in the cytosolic fraction.

CONCLUSION
Consequently, it can be seen that glucocorticosteroids are able to playa large roll in
the functioning of the human body, as well as in other animals. They are currently being
used as therapy to treat such conditions as skin inflammations and hypoglycemia. As
more becomes known about them and their beneficial and also possibly harmful effects, it
-13-

is likely that the medical and scientific worlds will receive great benefits. For example,
work is currently being done to determine if prenatal stress might possibly impair the
coping and regulation of the hypothalamic-pituitary-adrenal (HPA) axis. Typical
characteristics of prenatally stressed infants include attentional deficits, hyperanxiety, and
disturbed social behavior. These symptoms are often associated with dysregulation of the
HPA axis, characterized by decreased feedback inhibition of corticotropin-releasing
hormone and prolonged elevation of plasma glucocorticoids in response to stress. It has
been proposed that the impaired ability to deal with stressful situations by the prenatally
stressed infants may be a result of the action of maternal hormones released during
periods of stress. It is now believed that if enacted during a critical time in fetal
development, gestational stress may increase the probability of developing this disorder.
It is this type of research that will hopefully lead to a more useful knowledge of
glucocorticoids in the near future.
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1. Introduction
Corticosteroids are a naturally occurring hormone found in the equine body. They are released by
the adrenal cortex following a multi-step pathway in which the adrenal cortex is stimulated to produce
corticosteroids by the presence of Adrenocorticotropic Hormone (ACTH) in the bloodstream. When
levels of corticosteroids are elevated in the blood, endogenous production is decreased as a result of
feedback inhibition which directly affects levels of ACTH in the blood.
Because of the complexities involved in the feedback mechanism, administration of exogenous
ACTH or corticosteroids (i.e. dexamethasone) can upset the general balance. If corticosteroids are
given over an extended period of time, production of ACTH by the pituitary will decrease, thus
signaling the adrenal cortex to down-regulate its production of corticosteroids. This decrease in
stimulation by ACTH will cause the adrenal cortex to atrophy, and corticosteroid production will
either decrease or stop. If exogenous treatment is suddenly withheld, there is often a severe
endocrine imbalance due to an inability to produce endogenous corticosteroids.

In this study, dexamethasone will be administered to horses in two ways, either 1M or IV. One of
the most prominently excreted forms of corticosteroids in the body is cortisol (hydrocortisone).
However, the body cannot distinguish between cortisol and the different man-made analogues such
as dexamethasone. Thus, dexamethasone will be recognized as a natural corticosteroid, leading to
repression of the endogenous production of cortisol. By measuring the concentration of cortisol
levels in the blood, the overall success of the corticosteroid suppression can be determined for the
different routes of injection of dexamethasone.

The initial hypothesis is that blood cortisol

concentrations in horses will be equally suppressed in horses given dexamethasone intravenously as
in horses given dexamethasone 1M. Thus, either method of administration will lead to equal
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suppression of the pituitary-adrenal axis in nonnal horses. As Pars Intermedia Pituitary adenoma with
absent or mild clinical signs is currently diagnosed using a dexamethasone suppression test or a
combined dexamethasone suppression/thyroid releasing hormone test, this study will attempt to prove
that the two methods of injection are generally equivalent in their suppression of cortisol levels.

2. Materials and Methods
Six mixed breed horses between 4 and 17 years old and weighing between 398 and 629 kg (878
and 1,387 lb) were used. The horses were used in a random cross-over study where they were
randomly assigned to treatment groups by drawing IV or 1M from a hat Blood samples will then be
collected before dexamethasone injection and at three hour intervals following injection, concluding
with a sample at t==24 hours .. A two week washout period will follow, after which the horses will
be treated with the opposite route of dexamethasone administration, once again followed by
collection of samples.
Jugular vein catheters were inserted at 8 AM, and the initial blood samples were drawn at 8:30
AM, whereby they were immediately placed into an evacuated purple top tube containing EDTA.
Dexamethasone (40 micrograms/kg of body weight) was then administered. The remaining blood
samples were drawn at the specified times, and also placed into a tube containing EDT A.
Following collection, the blood samples were centrifuged, and the plasma was collected and stored
at -70 C until analyzed. Following thawing, cortisol concentration was then determined by use of the
Count-A-Coat radio-immunoassay procedure produced by Diagnostic Products Corporation. In this
procedure, 1-125 labeled cortisol competes for a fixed time with cortisol in the equine plasma sample
for antibody sites. Because the antibody is immobilized to the wall of a polypropylene tube, simply
-17-

decanting the supernatant suffices to terminate the competition and to isolate the antibody-bound
fraction of the radiolabeled cortisol. Counting the tube in a gamma counter then yields a nurrlber,
which converts by way of a calibration curve to a measure of the cortisol present in the patient
sample.
Means and SEM for cortisol concentrations were estimated using proc MEANS in SAS. Analysis
of variance was performed on data using the mixed procedure (pROC MIXED) in SAS to compare
time and treatment interactions. Significant differences were determined a P<O.05.

3. Results
The results showed that there was no difference in 1M versus IV treatment (P=.1878). There was
a significant decrease in cortisol over time (P<O.05). However, there was no time and treatment
interaction (P=. 9797).

4. Discussion

As was expected, cortisol concentrations were seen to decrease over time (Figure 1). The results
of this study showed that there was no significant difference in the overall suppression of cortisol
when dexamethasone was injected IV and 1M. Thus, both IV and 1M injection of dexamethasone
equally suppressed the pituitary-adrenal axis. In the future, this information will be useful to
practitioners in determining which route of administration is the best for testing for Pars Intermedia
Pituitary adenoma. Pituitary tumors are common in older horses and require blood testing for
diagnosis.

The current methods of diagnosing this disease require the administration of

dexamethasone (either 1M or IV) followed by IV administration of Thyroid Releasing Hormone. The
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blood cortisol concentration is then measured at prescribed time intervals after dexamethasone
injection.

Previously, there was no information on whether the route of dexamethasone

administration effected the interpretation of the test or whether there was a difference in cortisol
blood concentrations depending on the route of dexamethasone administration. However, the results
of this study have demonstrated that, in normal horses, the route of administration of dexamethasone
does not affect the result of the test used to diagnose pituitary tumors.

-19-
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Figure 1: Treatment with dexamethasone IM.
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Figure 2. Treatment with dexamethasone IV
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Figure 3. Combined results for dexamethasone IV and 1M
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The cover page, part I, General Information and all applicable sections of part II, Detailed Information must be completed
for all research and teaching activities.
Submit 3 typed copies to:
Office of laboratory Animal Care (OlAC)
A205 Veterinary Teaching Hospital
Phone # 974-5634

HORSE ENDOCRINOLOGY
Title of Project/Course

Frank M. Andrews, DVM
Principal Investigator/Instructor

423-974-5704
Wk, Phone

«(

Lg. Animal Clinical Sciences

UTCVM

Department

College

our signature as P,I., Co-investigator, or Department Head on this application verifies that: (1) the information herein is true
and correct and that you are familiar with and will comply with the legal standards of animal care and use established under
fed~:=!£nd state laws and policies as well as university policies; (2) the proposal has received approval for scientific and/or
ed/rnal merit by peer revie • nd (3) the activities do not unnecessarily duplicate previous experiments.

~
Date

Date
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PART I.
GENERAL INFORMATION

~.

To be completed for all Research and Teaching Activities.
General Information
1.

This is a [X] New [ ] 3-year rewrite proposal for
[ ] Research

~f

B.

II

[ ] Teaching

March 9, 1998

May 1, 1998

2.

Anticipated:

3.

[ ] Yes [X] No This protocol includes the use of farm animals used or intended for use as food or
fiber, or livestock or poultry used or for improving animal nutrition, breeding, management, or production
efficiency, or for improving the quality of food or fiber.

4.

Veterinarian responsible for clinical care
[ ] OLAC Staff Veterinarians
[X] Dr. Dallas Goble
[ ] LACS Ambulatory Service for the Department of Animal Science
[ ] Other, list
If other, clinical veterinarian must follow the IACUC "Attending
Veterinarian/Researcher Veterinarian" policy.

5.

Funding Source: Large Animal Clinical Sciences

start date

end date

Animal Housing Facilities

In order to provide assurance of humane care and use of laboratory animals, all animal housing facilities on the UTK
campus will be operated according to federal laws, AftALAC and NIH Guidelines, and the Guide for the Care and Use of
Agricultural Animals in Agricultural Research and Teaching as appropriate. Housing of animals, including those actively on
experiment, for periods longer than 12 hours, is restricted to facilities meeting such guidelines and laws.
Please check your preferred housing location.
[]
[]
[]
[X]
[]
[]
[]
[]

College of Arts and Sciences Facility in the Walters Life Sciences Building (WLS).
College of Human Ecology Animal Facility in the Jessie Harris Building.
College of Veterinary Medicine (CVM) Laboratory Animal Facility VTH/Cherokee
CVM Large Animal Clinical Sciences in VTH/Cherokee Farm
UT Medical Center Lab Animal Facility
Brehm Animal Science Building Room _ _ __
IACUC Approved Satellite Facility List bldg/room # _ _ _ _ _ _ _ _ _ _ __
*Other

*Any newly established facility must be approved before housing animals.
In accordance with NIH Guidelines and Federal Law, the IACUC formally reviews all animal housing facilities and satellites
semi-annually and files a report to the Office for Protection from Research Risks (OPRR) in Washington, DC and the
I 'f'lited States Department of Agriculture (USDA).

\.

"
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Part I.
General Information'
continued
Description of Animals

Common Name

Stra i nIB reed

Equine

2.

Sex

Weight/Age

Source

#/project

Maximum per day

F

6-30 yrs

UTCVM

6

6

Animals will be removed from the animal housing facility:

[X] No
[

3.

] Yes. Please answer the following:
1. Animals will be taken to (bldg/room number): _ _ _ _ _ _ _ __
2. Animal manipulations that will be performed in the laboratory include: _ _ _ _ __
3. Estimated total time period live animals will be kept in the laboratory:
hours
4. Animals will be returned to the facility YES NO

Disposal of animals after completion of activity:

[X] Return to production/breeding unit/facility inventory
[
[
[
[
[
[

]
]
]
]
]
]

Slaughter, (must conform to the Humane Slaughter of Livestock, 9 CFR, part 313)
Sold
Transfer to another research project (if yes, project title and investigator)
Euthanized
Returned to owner
Other (Please describe)_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

23

Non-Technical Summary
A complete non-technical summary is required for conformance with PHS Policy. Non-technical summary must be
submitted as an attachment and should not exceed mo (2) pages. Non-technical summary must be written to
ensure comprehension by non-scientists on an 8th grade level.
It must contain the following:
1) objectives of the research or teaching activity;
2) species and number of animals;
3) methods used to reduce any experimental stress or discomfort
4) schedule of the course or the study procedures performed on animals during each phase
5) benefits, outcome and results expected in non-technical terms.
Pituitary tumors are common in older horses and require blood testing for diagnosis. Current
methods of diagnosing this disease in horses requires the administration of dexamethasone either
intravenously (in the vein (IV)) or intramuscular (in the muscle (1M)) and Thyroid Releasing Hormone
IV and measurement of blood cortisol (steroid) concentration at prescribed time intervals after
injection. Unfortunately, there is no information on whether the route of dexamethasone
administration (IV vs. 1M) effects the interpretation of the test or whether there is a difference in
cortisol blood concentrations depending on the route of dexamethasone administration. The
objective of this study is to detennine if there is a difference in blood cortisol concentration in horses
given dexamethasone IV versus dexamethasone 1M. The data from this experiment will help
determine if the route of administration affects the results of the test in normal horses so that this test
can be used as a diagnostic test in horses suspected of having pituitary adenoma.
We propose to use 6 healthy 7·30 year old horses. This is the age range in which the disease
occurs in horses.
The horses will be placed in box stall during the 24 hour blood collection phase with feed and
water to minimize stress. At approximately 8:00 am in the morning the horses will be placed in an
equine stocks with a rope tied in front and behind. The horses will be lightly restrained !'lith a lead
shank and halter and area over the jugular vein clipped and prepared with provodone iodine sterile
scrub. Lidocaine (approximatery 3 cc) will be injected subcutaneously over the jugular vein to locally
anesthetize the skin to the minimize pain of catheter placement. The intravenous catheter will be
placed in the vein and sutured in place to prevent the horse from removal during the study period.
The horse will then be place in the stall and blood sampling started at approximately 8:30 pm (T=O).
After the first blood sample is drawn then the horse will be injected with a low dose of dexamethasone
(40lJg/kg, IV or 1M). A blood samples will be taken 3 hour after injection, then TRH (1.0 mg, IV) will be
administered. Blood samples will then be taken at 3.5, 6, 9, 12, 18, and 24 hours after administration
of dexamethasone. Each horse will receive the dexamethasone IV followed by a two week rest, then
receive the dexamethasone 1M in the same manner. Some horses will receive the injections in reverse
order to remove any bias due to effect of treatment. The blood samples will be analyzed later for
cortisol concentrations.
We expect to determine if the route of dexamethasone administration effects the cortisol
concentrations measured. This information will help practitioners in determining which route of
administration is the best for using this diagnostiC test to determine horses that have pituitary
adenoma.

E.

Flow Sheet or Table of Groupings
Pertinent information (Le., numbers of animals, experimental manipulations) should be provided on a flow
sheet. The Committee members should be able to follow every manipulation of the animal from
experiment initiation to completion (e.g., day one, group one, treatment; day two. etc.). Please provide as
a separate page.
See attached Page
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Flow Sh~etor Table of Groupings
Pertinent information (Le., numbers of animals. experimental manipulations) should be provided on a flow
sheet. The Committee members should be able to follow every manipulation of the animal from
experiment initiation to completion {e.g., day one, group one, treatment; day two. etc.}. Please provide as
a separate page.

Flow Sheet

8:00 am-horses placed in equine stocks and IV jugular catheter placed.
8:30 am-blood sample taken, Dexamethasone (40 pg/kg, IV) administered.
11 :30 am-blood sample taken, TRH (1.0 mg, IV) administered.
12:00 pm-blood sample taken
2:30 pm-blood sample taken
5:30 pm-blood sample taken
8:30 pm-blood sample taken
11 :30 am-blood sample taken
2:30 am-blood sample taken
5:30 am-blood sample taken
8:30 am-blood sample taken
IV catheter removed and horse returned to stall or pasture at Cherokee
Same protocol repeated 2 weeks later with 1M injection of Dexamethasone.

\
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F.

Qualifications of Personnel

list all individuals who will be working with the animals on this project. Include all investigators, student
employees, post-doctoral researchers, staff research associates and laboratory assistants who will
actually work with the animals. If personnel do not have experience, state how they wifl be trained.
The Occupational Health Program (OHP) is available for all personnel who work with laboratory
animals. Any personnel in a high risk category (e.g. handling primates, wild animals or any animals at risk
of infection with rabies) must participate.

OHP*

N an1elDegree( s)
Dr. Frank M. Andrews
Janell Kapp (Student)

Procedure(s)/Description of Relevant Experience
IV catheter placement, injection of pharmaceutical agents, collection of
bloodlDr. Andrews has experience as veterinarian and previous
experience with pharmaceutical agents used per UT-ACUC# 665.
Will assist Dr. Andrews in above procedures. She has been trained by
Dr. Andrews in the above procedures.

..

*If an individual having animal contact IS not currently enrolled In the occupational health program call the
OLAC (974-5634) for information on enrolling.

G.

Animal Welfare

1.

This project involves pain or distress [ ] yes [X] no
The USDA (Policy #12) requires that the principal Investigator must provide a written
narrative of the sources consulted to-determine whether alternatives"or refinements exist·
to procedures which may reduce pain or distress.
If yes. the minimal written narrative should include:
a.
b.
c.
d.

the databases searched or other sources consulted,
the date of the search and the years covered by the search,
key words and/or search strategy used,
a narrative written in such a way that the IACUC can readily assess whether the
search topics were appropriate and whether the search was sufficiently thorough

2.

Does the proposed research duplicate any previous work? [ ] yes [X] no If yes, explain why it
is scientifically necessary to replicate the experiment.

3.

Why have you selected the particular species proposed in this project?

To improve a diagnostic procedure for pituitary tumors in horses.
4.

Provide an explanation of how the numbers of animals to be used were derived. If used in an
experiment (test a hypothesis) numbers should be based on scientific and statistical requirements
(power tests) to achieve objectives.

In previous experiments we have determined variability in plasma cortisol. Six
horses are sufficient for this purpose.
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PART II.
DETAILED INFORMATION
Check and complete those sections A - E that are relevant to your project.
REMOVE ALL SECTIONS NOT APPLICABLE TO YOUR PROPOSAL.

A.

Non-Surgical Procedures (Pertains to any experimental procedureincluding non-surgicat pre-surgical and post-surgical procedures using animals)

[ ] NO

B.

Surgical Procedures (Pertains to any surgical procedure, including non-survival surgery. If other
procedures are done on animals prior to or after surgery, comprete section A and other applicable
sections.)

[X]NO

C.

[ ] YES: COMPLETE SECTION C

Hazardous Agents/Prescription Drugs/Controlled Substances

[X] NO

E.

[ ] YES: COMPLETE SECTION 8

Field Studies Involving Wild Animals (Request this section from the OLAC office)

[X] NO

D.

[ X] YES: COMPLETE SECTION A

[ ] YES: COMPLETE SECTION 0

Euthanasia

[Xl NO

[ ] YES: COMPLETE SECTION E
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II

Part II
Section A .
Non-Surgical Procedures

1.

2.

Sites of Study

a.

Site of housing prior to study:-.::C=;.V..:.....oo..:M~C=h=e=r-"'o=k=e=e~F-""a=r=m.::...-_ _ _ _ _ _ _ _ _ __
Bldg.
Room/pen

b.

Site of experimental work: CVM Cherokee Farm
Bldg.

Room/pen

Health Assessment:
How often and by whom will the clinical condition of animals be monitored?
Once before the experiment is conducted and daily during the investigation.
What are the anticipated health changes?
None

What methods will be used to monitor health changes?
Temperature, Pulse, and Respiratory Rate, general physical examinations and observation
What criteria will be used for removing animals from the study prematurely?
Any animal exhibiting any abnormal clinical sign, including increased heart rate, respiratory rate, or
temperature.

(r
3.

Study Procedures: Please check the following items that apply and fill out appropriate parts of this section.
[
[
[
[
[
[

] Polyclonal Antibody production*
X] Blood* or other body fluid withdrawal, tissue collection, injections
] Restraint with mechanical devices
] Projects involving nutritional deficiencies, tumor and disease models or toxicity testing
] Anesthesia or analgesia* (for non-surgical procedures)
] Behavioral Studies

* The IACUC has approved guidelines for these procedures. Deviations must be justified.
Polyclonal Antibody production
Describe procedure. antigen and adjuvants used, the ratio of antigen to adjuvant and routes and volumes of injection: (Vol.
should be < 0.25 ml per injection site; subcutaneous route is recommended)

Blood or body fluid withdrawal/tissue collectionl injections
Describe in detail method(s). needle sizes, volume(s) collected or administered. and frequency of collection or injections:
Blood will be collected from the preplaced 16 ga 5 ~ inch IV catheters using a syringe. 10ml samples will
be collected at O-time, 3, 3.5, 6, 9, 12, 15, 18, and 24 hours after injections of dexamethasone.
Approxinlately, 190 ml of blood will be taken from each horse, ,vhich comprises less than 0.5% of the
total blood volume of a 450 kg (1000 Ib) horse. By preplacing the catheter we will avoid having to stick
(e horse ,vith needles 9 times during the 24 hour period.
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Part II
Section A .. Non-Surgical Procedures
continued

Describe device, duration of restraint, frequency of observation, conditioning procedures and steps to assure comfort and
well-being:
The horses wiIJ be lightly restrained in an equine stocks for intravenous catheter placement and housed in a box
stall and restrained with a lead shank and halter for blood collections.
Behavioral Studies
Describe in detail types of behavioral manipulations, including placement in testing chambers or apparatus, use of aversive
stimuli, duration of test periods, and frequency of test periods.
N/A

Nutritional deficiencies/Ascites tumor, monoclonal
antibody production/Disease. neoplasia modelslToxicity testing
Describe methodology. State objective criteria used to assess physical condition and pain and distress during course of
study_ Include clinical signs or manifestations expected from the procedure. What criteria will be used to determine a
humane endpoint before severe morbidity and death?
N/A

(
Anesthesia/AnalgesialTranquilization (Other than Surgery Section B)
Adequate records describing anesthetic monitoring and recovery must be maintained and available to the
attending veterinarian and animal care staff.
Drug

Dose

Frequency

Route

For which procedure

Name and qualifications of person administering drugs: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Describe: frequency and methods to be used to monitor level of anesthesia (e.g., blood pressure, heart rate, pedal reflex,
jaw tone); the anticipated duration for recovery from anesthesia; how often will the animals be monitored and by whom.
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RESUl-TS OF OE)( SUPPRESSION TEST
SPORT

C·t-O

t=1a
t=1b
t=1 average
t;:2a
t=2b
t=2 average
t=3

t;:4
t=5
t=6
t=7
t;::8
t=9a
t=9b
t=9 average
t;;10a
t=10b
t= 10 average

1M - 3/11/96

IV - 411/98

69.998

78.073
26.75
37,284

21.2
22,557

21.8765

32.017

22.974

21.176
29.888

18.48

25.532
13.261
7.1824

20.727
12.531

8.5252
7.3274

6.2296
5.3764

6.0833
5,5979
4.1229
5.8712
4.2302
5.0506

4.3809
4.2942

13.757

3.7348
5.3456
4.5402
83.705

12.785

20.421

13.271

52,063

(

(
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BEE

C~

t=O
t;;1a
t=1b
t=1 average
t=2a
t;;:2b
t=2 average
t=3
t=4
t-5
t=6
t=7
t=8
t;.::9a
t=9b
t=9 average
t=10a
t;;10b
t= 10 average

1M - 3/13/98
46.154
12.528
12.653
12.5905
11.114
12.557
11.8355
6.9263
7,3145
7.3133
6.8168
4.5605
8.4522
10.408
7.0322
6,7201
10.669
9.557
10.113

IV - 4/1/96
75.915
22.845
22.325
22.585
19.112
19.641
19.3765
11.001
7.24Q8
5.5151
4.3959
5.1187
4.8861
5.883
7.4805
6.66175
10,64
12.442
11.641

(
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97015
t=O

C.
,J

t=1a
t=1b
t=1 average
t;:28
t=2b
t=2 average
t=3
t-4
t=5
t=6
t=7
t=8
t=9a
t=9b
t=9 average
t .. 108
t=10b
t=10 average

IV - 3/13/96

1M - 4/8196
77.461
53.144
43.266
48.205
38.01
40.286
39.148
13,228
7.2369
6.3026
7.765
5.7711
4.5962
5.7912

79.454
29.553
25.988
27,7705
20.401
17.288
18,8445
9.3124
8.8875
8.9025
14.227
5.2055
10.825
10.901
10.863
11.765
8.4247

5.0388
5.415
12.312
12.858

12.585

10.09465

(

(
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97008
t=O

C t;1a
p

t=1b
t=1 average
t=2a
t-2b
t=2 average
t=3
t=4
t;:5
t=6
t=7
t=8
t-9a
t=9b
t=9 average
t=10a
t;;10b
t= 10 average

IV - 3/13/98

1M - 4/6198
127,02
28.67
26.536
27,603
21.636
20.476
21.056
11.424
8.7517
9.3114
7.319
9.3906

114.26
37.08
34.077
35,5785
32,16
27.959
30.0595
16.377
10.152
7.0485
5.3818

5.3365

6.0063

7.0399
6.4836
6.76175
10.746
8.4669
9.60645

6.9891
5.1593
6.0742
7.9763
8.4617
8.219
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97009
t;;:O
t=1a
( ..- t=1b
t=1 average
t-;2a
t=2b
t=2 average
t=3
t-4
t=5
t=6
t=7
t=8
t=9a
t=9b
t=9 average
t;;;10a
t=10b
t= 1Q average

1M - 3/13198

IV - 4115/98

129.24
47.606
38.678
43.142
32.973
29.192
31.0825
19.759
16.39
9.973
7.4113

64.426
18.219
23.173
20.696
20.641
17.293
18.967
8.6819
10.369
12.011
5.641
5,9264
5.0389
16.854
13.458
15.156
51.02
55.188
53.104

8.5624
10.64
7.9084
9.2742
49.438
52.093
50.7655

(

(
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97018

C

t;;:O
t=1a
t=1b
t=1 average
t-2a
t=2b
t=2 average
t=3
t-4
t=5
t=6
t=7
t;;.;8
t=9a
t=9b
t=9 average
t;;;10a
t=10b
t= 10 average

IV - 3/13/98

1M - 4/15/98

163.19
56.487
51.607
54.047
45.155
41.21
43.1825
20.556
9.5262
10.155
6.3578

95.919
37.39
34.373
35.8815
28.714
25.88
27.297
12,586
9.7436
6.3317
8.3979
4,1931
5.2392
4.3358
3.7229
4.02935
27.97
28.417
28.1935

55.39
54.402
41.587
47.9945
99.443
92.192
95.8175

(
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